ArticleNature2026
Genetic predictors of GLP1 receptor agonist weight loss and side effects.
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists.Diabetes care · 2026Article
- Improving Medication Classification in GLP-1RA Research: Feasibility of a Photo-Review Protocol.Obesity science & practice · 2026Article
- GLP-1 drugs fail to help some people lose weight - scientists are on a quest for answers.Nature · 2026Article
- Commentary on: Genetic predictors of GLP1 receptor agonist weight loss and side effects (Nature volume 653, pages 770-775 (2026)).Journal of diabetes investigation · 2026Article
- GLP-1 receptor agonists beyond glycemic control: integrated cardio-renal-metabolic protection across the cardiovascular kidney metabolic continuum.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Genetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesity.Life (Basel, Switzerland) · 2026Review
- Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of "Ozempic Face".Dermatology and therapy · 2026Article
- Precision nutrition testing is the future of personalized care: evidence and coverage policies for equitable access.Health affairs scholar · 2026Article
- Review
- Current status of anti-obesity medications and performance, an EHR based survey.BMC endocrine disorders · 2026Article
- Update on Obesity and Its Relationship to Atherosclerotic Cardiovascular Disease and Associated Risk Factors.Journal of clinical medicine · 2026Review
- Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies.Metabolites · 2026Review
- Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Predictors of treatment response to semaglutide for weight management.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of glucagon-like peptide 1 (GLP1) receptor agonists, including semaglutide and tirzepatide, has transformed the clinical management of overweight and obesity. However, substantial inter-person variability exists in both weight loss efficacy and the incidence of side effects
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.